Wooree Bio Co.,Ltd

KOSDAQ:A082850 Stock Report

Market Cap: ₩43.1b

Wooree BioLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Wooree BioLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Semiconductor earnings growth27.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article May 16

Wooree BioLtd (KOSDAQ:082850) Could Be Struggling To Allocate Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Analysis Article Mar 28

Why Wooree BioLtd's (KOSDAQ:082850) Shaky Earnings Are Just The Beginning Of Its Problems

Wooree Bio Co.,Ltd's ( KOSDAQ:082850 ) recent weak earnings report didn't cause a big stock movement. However, we...
Analysis Article Dec 16

Does Wooree BioLtd (KOSDAQ:082850) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Oct 23

Risks Still Elevated At These Prices As Wooree Bio Co.,Ltd (KOSDAQ:082850) Shares Dive 28%

Wooree Bio Co.,Ltd ( KOSDAQ:082850 ) shares have had a horrible month, losing 28% after a relatively good period...
Analysis Article Sep 07

Risks Still Elevated At These Prices As Wooree Bio Co.,Ltd (KOSDAQ:082850) Shares Dive 27%

The Wooree Bio Co.,Ltd ( KOSDAQ:082850 ) share price has softened a substantial 27% over the previous 30 days, handing...
Analysis Article Aug 30

Wooree BioLtd (KOSDAQ:082850) Hasn't Managed To Accelerate Its Returns

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysis Article Aug 10

Is Wooree BioLtd (KOSDAQ:082850) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Jul 19

Wooree Bio Co.,Ltd's (KOSDAQ:082850) Shares Climb 37% But Its Business Is Yet to Catch Up

Despite an already strong run, Wooree Bio Co.,Ltd ( KOSDAQ:082850 ) shares have been powering on, with a gain of 37% in...
Analysis Article May 25

Wooree BioLtd's (KOSDAQ:082850) Earnings Seem To Be Promising

Shareholders appeared to be happy with Wooree Bio Co.,Ltd's ( KOSDAQ:082850 ) solid earnings report last week. Looking...
Analysis Article May 03

These 4 Measures Indicate That Wooree BioLtd (KOSDAQ:082850) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article Apr 26

Wooree Bio Co.,Ltd's (KOSDAQ:082850) Share Price Boosted 50% But Its Business Prospects Need A Lift Too

Wooree Bio Co.,Ltd ( KOSDAQ:082850 ) shares have had a really impressive month, gaining 50% after a shaky period...
Analysis Article Feb 28

Should You Invest In Wooree BioLtd (KOSDAQ:082850)?

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...
Analysis Article Feb 01

Here's Why Wooree BioLtd (KOSDAQ:082850) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Jan 12

Is Wooree Bio Co.,Ltd's (KOSDAQ:082850) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Wooree BioLtd (KOSDAQ:082850) has had a great run on the share market with its stock up by a significant 58% over the...
Analysis Article Dec 21

Wooree BioLtd (KOSDAQ:082850) Shareholders Have Enjoyed A Whopping 478% Share Price Gain

The Wooree Bio Co.,Ltd ( KOSDAQ:082850 ) share price has had a bad week, falling 17%. But over the last year the share...
Analysis Article Nov 29

Here's Why We Think Wooree BioLtd's (KOSDAQ:082850) Statutory Earnings Might Be Conservative

As a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wooree BioLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A082850 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20261,014,857-6,67868,24590,250N/A
12/31/20251,043,962-9,37412,76634,823N/A
9/30/20251,083,198-13,9895,31229,501N/A
6/30/20251,167,655-12,925-34,69048,083N/A
3/31/20251,243,3242,012-93,416-9,692N/A
12/31/20241,237,1984,743-46,88336,240N/A
9/30/20241,263,7038,665-27,94049,369N/A
6/30/20241,303,98215,86625,73944,173N/A
3/31/20241,288,39116,26144,46854,973N/A
12/31/20231,263,94415,58115,94926,515N/A
9/30/20231,210,01812,899-3,7877,103N/A
6/30/20231,168,69010,40410,47220,860N/A
3/31/20231,272,91115,98713,92124,851N/A
12/31/20221,355,05621,82229,92843,353N/A
9/30/20221,483,23131,10742,63258,779N/A
6/30/20221,528,81932,78551,62864,832N/A
3/31/20221,527,45230,71123,08138,679N/A
12/31/20211,543,31233,15637,44350,208N/A
9/30/20211,577,02123,35120,24731,361N/A
6/30/20211,668,10823,94934,86248,264N/A
3/31/20211,621,46723,28861,41776,607N/A
12/31/20201,623,38316,84151,32869,427N/A
9/30/20201,600,03121,43870,13387,897N/A
6/30/20201,580,79617,50312,24431,127N/A
3/31/20201,682,9153,72954,39474,655N/A
12/31/20191,672,6484,532N/A65,803N/A
9/30/20191,635,873-2,060N/A35,163N/A
6/30/20191,539,163-10,321N/A66,582N/A
3/31/20191,358,099-18,184N/A15,941N/A
12/31/20181,279,627-32,888N/A10,824N/A
9/30/20181,343,043-46,169N/A18,908N/A
6/30/20181,258,947-43,525N/A63,020N/A
3/31/20181,359,443-33,208N/A22,586N/A
12/31/20171,474,632-28,041N/A27,730N/A
9/30/20171,391,349-4,458N/A22,482N/A
6/30/20171,497,664-11,950N/A-12,865N/A
3/31/20171,489,526-21,295N/A20,483N/A
12/31/20161,533,519-23,261N/A-1,948N/A
9/30/20161,290,944-57,516N/A-1,215N/A
6/30/20161,327,188-55,845N/A16,492N/A
3/31/20161,803,498-48,526N/A-3,492N/A
12/31/20151,764,595-42,887N/A-11,529N/A
9/30/20152,055,453-19,841N/A53,573N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A082850's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A082850's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A082850's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A082850's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A082850's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A082850's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/01 18:02
End of Day Share Price 2026/07/31 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wooree Bio Co.,Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan RheeCitigroup Inc
Sang Hyeon ParkiM Securities
Jong Woo YooKorea Investment & Securities Co., Ltd.